Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Inhibrx Biosciences (INBX) Non Operating Income (2023 - 2025)

Inhibrx Biosciences (INBX) has disclosed Non Operating Income for 3 consecutive years, with -$1.9 million as the latest value for Q4 2025.

  • Quarterly Non Operating Income fell 100.09% to -$1.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$4.7 million through Dec 2025, down 100.12% year-over-year, with the annual reading at -$5.0 million for FY2025, 100.25% down from the prior year.
  • Non Operating Income for Q4 2025 was -$1.9 million at Inhibrx Biosciences, down from -$1.4 million in the prior quarter.
  • The five-year high for Non Operating Income was $2.0 billion in Q4 2024, with the low at -$1.9 million in Q4 2025.
  • Average Non Operating Income over 3 years is $368.4 million, with a median of -$59000.0 recorded in 2024.
  • The sharpest move saw Non Operating Income surged 930473.73% in 2024, then crashed 149.23% in 2025.
  • Over 3 years, Non Operating Income stood at $16.2 million in 2023, then skyrocketed by 12333.84% to $2.0 billion in 2024, then plummeted by 100.09% to -$1.9 million in 2025.
  • According to Business Quant data, Non Operating Income over the past three periods came in at -$1.9 million, -$1.4 million, and -$1.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.